EUVIMEDEUVIMED entdecken
Crossref

Prognostic nutritional index predicts the prognostic impact of avelumab maintenance therapy in patients with advanced urothelial carcinoma: results from the Chu-shikoku Japan Urological Consortium

Hideo Fukuhara iD, Shingo Nishimura, Keita Kobayashi iD, Kenichi Nishimura, Yoichiro Tohi iD, Ryu Shigehisa, Atsushi Takamoto iD, Ryutaro Shimizu, Ryotaro Tomida, Kohei Ogawa, Satoshi Katayama iD, Shinkuro Yamamoto und 8 weitere

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Hideo Fukuhara und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kochi Medical School, 185-1 Kohasu, Oko-cho, Nankoku city, Kochi, 783-8505, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nutrition Assessment, Carcinoma, Transitional Cell, Urologic Neoplasms. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Avelumab maintenance therapy is the standard treatment for locally advanced or metastatic urothelial carcinoma (mUC) demonstrating a response to platinum-based first-line therapy. Prognostic markers are necessary to predict the prognostic efficacy of avelumab therapy. This retrospective study investigated prognostic markers to optimize the efficacy of avelumab maintenance therapy.

Methods

This retrospective cohort study enrolled a total of 91 patients diagnosed with locally advanced or mUC and who received avelumab maintenance therapy between February 2021 and September 2024. The impacts of neutrophil-to-lymphocyte ratio (NLR), prognostic nutritional index (PNI), hemoglobin (Hb) level, and Creactive protein (CRP) level on overall survival (OS) were evaluated using Kaplan-Meier method and Cox proportional hazards model.

Results

The patients with pretreatment PNI ≥ 40.2 [hazard ratio (HR) 0.15; 95% confidence interval (CI), 0.04–0.57] and pretreatment Hb ≥ 10.4 g/dl (HR 3.05; 95% CI, 1.53–6.09) were significantly associated with longer OS. In univariate analysis, significant prognostic factors for OS were identified as the number of cycles of avelumab ≥11 (P = .042), pretreatment Hb level ≥ 10.4 g/dl (P = .015), and pretreatment PNI ≥ 40.2 (P = .002). The multivariate Cox regression analysis demonstrated that pretreatment PNI ≥ 40.2 (HR 0.22; 95% CI: 0.56–0.86, P = .03) was identified as a significant prognostic factor for OS.

Conclusions

Pretreatment low PNI was associated with poor survival outcome in avelumab maintenance therapy. This finding provides support for the potential role of PNI as a prognostic factor of avelumab maintenance therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNutrition AssessmentCarcinoma, Transitional CellUrologic NeoplasmsHumansMaleFemaleAgedRetrospective StudiesPrognosisJapanMiddle AgedAged, 80 and overMaintenance Chemotherapy

Stichwörter der Autor:innen

avelumabprognostic nutritional indexurothelial carcinoma

Substanzen

avelumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Kochi Medical School, 185-1 Kohasu, Oko-cho, Nankoku city, Kochi, 783-8505, Japan.
  • Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
  • Department of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1, minamikogushi, Ube, Yamaguchi, 755-8505, Japan.
  • Department of Urology, Ehime University, 454 Shizugawa, Toon, Ehime, 791-0295, Japan.
  • Department of Urology, Faculty of Medicine, Kagawa University, 1750-2, Ikedo, Mikicho, Kidagun, Kagawa, 761-0793, Japan.
  • Department of Urology, Fukuyama City Hospital, 5-23-1 Zao-cho, Fukuyama, Hiroshima, 721-8511, Japan.

ORCID-Profile: Hideo Fukuhara, Keita Kobayashi, Yoichiro Tohi, Atsushi Takamoto, Satoshi Katayama, Takuma Kato, Koji Shiraishi

Zitieren

APA

Fukuhara, H., Nishimura, S., Kobayashi, K., Nishimura, K., Tohi, Y., Shigehisa, R., Takamoto, A., Shimizu, R., Tomida, R., Ogawa, K., Katayama, S., Yamamoto, S., Bekku, K., Miura, N., Kato, T., Morizane, S., Wada, K., Furukawa, J., Shiraishi, K., & Inoue, K. (2025). Prognostic nutritional index predicts the prognostic impact of avelumab maintenance therapy in patients with advanced urothelial carcinoma: results from the Chu-shikoku Japan Urological Consortium. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf208

Vancouver

Fukuhara H, Nishimura S, Kobayashi K, Nishimura K, Tohi Y, Shigehisa R, et al. Prognostic nutritional index predicts the prognostic impact of avelumab maintenance therapy in patients with advanced urothelial carcinoma: results from the Chu-shikoku Japan Urological Consortium. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf208

BibTeX
@article{Fukuhara2025,
  author = {Fukuhara, Hideo and Nishimura, Shingo and Kobayashi, Keita and Nishimura, Kenichi and Tohi, Yoichiro and Shigehisa, Ryu and Takamoto, Atsushi and Shimizu, Ryutaro and Tomida, Ryotaro and Ogawa, Kohei and Katayama, Satoshi and Yamamoto, Shinkuro and Bekku, Kensuke and Miura, Noriyoshi and Kato, Takuma and Morizane, Shuichi and Wada, Koichiro and Furukawa, Junya and Shiraishi, Koji and Inoue, Keiji},
  title = {Prognostic nutritional index predicts the prognostic impact of avelumab maintenance therapy in patients with advanced urothelial carcinoma: results from the Chu-shikoku Japan Urological Consortium},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf208}
}
Kostenlos starten →